maprotiline. Either increases toxicity of the other by sedation. Use Caution/Monitor.brexpiprazolebrexpiprazole and maprotiline both increase sedation. Use Caution/Monitor.brimonidinebrimonidine and maprotiline both increase sedation. Use Caution/Monitor.brivaracetambrivaracetam and maprotiline both increase sedation. Use Caution/Monitor.brompheniraminebrompheniramine and maprotiline both increase sedation. Use Caution/Monitor.buprenorphinebuprenorphine and maprotiline both increase sedation. Use Caution/Monitor.buprenorphine and maprotiline both increase QTc interval. Use Caution/Monitor.buprenorphine buccalbuprenorphine buccal and maprotiline both increase sedation. Use Caution/Monitor.buprenorphine buccal and maprotiline both increase QTc interval. Use Caution/Monitor.buprenorphine subdermal implantmaprotiline, buprenorphine subdermal implant. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.buprenorphine subdermal implant and maprotiline both increase QTc interval. Use Caution/Monitor.buprenorphine transdermalbuprenorphine transdermal and maprotiline both increase QTc interval. Use Caution/Monitor.buprenorphine, long-acting injectionmaprotiline, buprenorphine, long-acting injection. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.buprenorphine, long-acting injection and maprotiline both increase QTc interval. Use Caution/Monitor.bupropionmaprotiline increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible.bupropion will increase the level or effect of maprotiline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.butabarbitalbutabarbital and maprotiline both increase sedation. Use Caution/Monitor.butalbitalbutalbital and maprotiline both increase sedation. Use Caution/Monitor.butorphanolbutorphanol and maprotiline both increase sedation. Use Caution/Monitor.caffeinemaprotiline increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbacholcarbachol increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbinoxaminecarbinoxamine and maprotiline both increase sedation. Use Caution/Monitor.carisoprodolcarisoprodol and maprotiline both increase sedation. Use Caution/Monitor.cevimelinecevimeline increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.chloral hydratechloral hydrate and maprotiline both increase sedation. Use Caution/Monitor.chlordiazepoxidechlordiazepoxide and maprotiline both increase sedation. Use Caution/Monitor.chlorpheniraminechlorpheniramine and maprotiline both increase sedation. Use Caution/Monitor.chlorpromazinechlorpromazine and maprotiline both increase sedation. Use Caution/Monitor.chlorzoxazonechlorzoxazone and maprotiline both increase sedation. Use Caution/Monitor.cinnarizinecinnarizine and maprotiline both increase sedation. Use Caution/Monitor.cisatracuriumcisatracurium and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.citalopramcitalopram and maprotiline both increase serotonin levels. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.clemastineclemastine and maprotiline both increase sedation. Use Caution/Monitor.clobazamclobazam will increase the level or effect of maprotiline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly. maprotiline, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).clomipramineclomipramine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramine and maprotiline both increase sedation. Use Caution/Monitor.clonazepamclonazepam and maprotiline both increase sedation. Use Caution/Monitor.clorazepateclorazepate and maprotiline both increase sedation. Use Caution/Monitor.clozapineclozapine and maprotiline both increase sedation. Use Caution/Monitor.cocaine topicalmaprotiline and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.codeinecodeine and maprotiline both increase sedation. Use Caution/Monitor.crizotinibcrizotinib and maprotiline both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.cyclizinecyclizine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclizine and maprotiline both increase sedation. Use Caution/Monitor.cyclobenzaprinecyclobenzaprine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprine and maprotiline both increase sedation. Use Caution/Monitor.cyproheptadinecyproheptadine and maprotiline both increase sedation. Use Caution/Monitor.dantrolenedantrolene and maprotiline both increase sedation. Use Caution/Monitor.daridorexantmaprotiline and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacindarifenacin and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.dasatinibmaprotiline and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.debrisoquinemaprotiline decreases effects of debrisoquine by Other (see comment). Use Caution/Monitor. Comment: Inhibition of uptake by adrenergic neurons.degarelixdegarelix and maprotiline both increase QTc interval. Use Caution/Monitor.desfluranedesflurane and maprotiline both increase sedation. Use Caution/Monitor.desipraminedesipramine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramine and maprotiline both increase sedation. Use Caution/Monitor.deutetrabenazinedeutetrabenazine and maprotiline both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).dexchlorpheniraminedexchlorpheniramine and maprotiline both increase sedation. Use Caution/Monitor.dexfenfluraminemaprotiline increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.maprotiline and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.dexmedetomidinedexmedetomidine and maprotiline both increase sedation. Use Caution/Monitor.dexmethylphenidatemaprotiline increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetaminemaprotiline increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.maprotiline and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.maprotiline increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor.dextroamphetamine transdermalmaprotiline, dextroamphetamine transdermal. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s).dextromoramidedextromoramide and maprotiline both increase sedation. Use Caution/Monitor.diamorphinediamorphine and maprotiline both increase sedation. Use Caution/Monitor.diazepamdiazepam and maprotiline both increase sedation. Use Caution/Monitor.diazepam intranasaldiazepam intranasal, maprotiline. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.dicyclominedicyclomine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.diethylpropionmaprotiline increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalindifelikefalin and maprotiline both increase sedation. Use Caution/Monitor.difenoxin hcldifenoxin hcl and maprotiline both increase sedation. Use Caution/Monitor.dihydroergotaminemaprotiline and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.dihydroergotamine intranasalmaprotiline and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.dimenhydrinatedimenhydrinate and maprotiline both increase sedation. Use Caution/Monitor.diphenhydraminediphenhydramine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.diphenhydramine and maprotiline both increase sedation. Use Caution/Monitor.diphenoxylate hcldiphenoxylate hcl and maprotiline both increase sedation. Use Caution/Monitor.dipipanonedipipanone and maprotiline both increase sedation. Use Caution/Monitor.dobutaminemaprotiline increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dolasetronmaprotiline and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.donepezildonepezil increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.donepezil and maprotiline both increase QTc interval. Use Caution/Monitor.dopaminemaprotiline increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dopexaminemaprotiline increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.doxepindoxepin and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepin and maprotiline both increase sedation. Use Caution/Monitor.doxylaminedoxylamine and maprotiline both increase sedation. Use Caution/Monitor.droperidoldroperidol and maprotiline both increase sedation. Use Caution/Monitor.echothiophate iodideechothiophate iodide increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.efavirenzefavirenz and maprotiline both increase QTc interval. Use Caution/Monitor.eletriptaneletriptan and maprotiline both increase serotonin levels. Modify Therapy/Monitor Closely.eliglustateliglustat increases levels of maprotiline by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.elvitegravir/cobicistat/emtricitabine/tenofovir DFelvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of maprotiline by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.ephedrinemaprotiline increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.maprotiline increases effects of ephedrine by unknown mechanism. Use Caution/Monitor.epinephrinemaprotiline increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.maprotiline increases effects of epinephrine by unknown mechanism. Use Caution/Monitor.epinephrine racemicmaprotiline increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.maprotiline increases effects of epinephrine racemic by unknown mechanism. Use Caution/Monitor.ergotaminemaprotiline and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.escitalopramescitalopram increases toxicity of maprotiline by QTc interval. Use Caution/Monitor.esketamine intranasalesketamine intranasal, maprotiline. Either increases toxicity of the other by sedation. Use Caution/Monitor.estazolamestazolam and maprotiline both increase sedation. Use Caution/Monitor.ethanolmaprotiline and ethanol both increase sedation. Use Caution/Monitor.etomidateetomidate and maprotiline both increase sedation. Use Caution/Monitor.ezogabineezogabine, maprotiline. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.fedratinibfedratinib will increase the level or effect of maprotiline by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.fenfluraminemaprotiline increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.maprotiline and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.fenfluramine, maprotiline. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.fesoterodinefesoterodine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.fingolimodfingolimod and maprotiline both increase QTc interval. Use Caution/Monitor.flavoxateflavoxate and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.flecainidemaprotiline and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.fluoxetinemaprotiline and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazinefluphenazine and maprotiline both increase sedation. Use Caution/Monitor.flurazepamflurazepam and maprotiline both increase sedation. Use Caution/Monitor.fluvoxaminefluvoxamine and maprotiline both increase QTc interval. Modify Therapy/Monitor Closely.formoterolmaprotiline increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.foscarnetmaprotiline and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.frovatriptanfrovatriptan and maprotiline both increase serotonin levels. Modify Therapy/Monitor Closely.gabapentingabapentin, maprotiline. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.gabapentin enacarbilgabapentin enacarbil, maprotiline. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.galantaminegalantamine increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.ganaxolonemaprotiline and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacingemifloxacin and maprotiline both increase QTc interval. Use Caution/Monitor.gilteritinibgilteritinib and maprotiline both increase QTc interval. Use Caution/Monitor.glycopyrrolateglycopyrrolate and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.maprotiline increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor.glycopyrrolate inhaledglycopyrrolate inhaled and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.maprotiline increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor.granisetrongranisetron and maprotiline both increase QTc interval. Use Caution/Monitor.haloperidolhaloperidol and maprotiline both increase sedation. Use Caution/Monitor.henbanehenbane and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropinehomatropine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine Ahuperzine A increases and maprotiline decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hydrocodonehydrocodone, maprotiline. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.hydromorphonehydromorphone and maprotiline both increase sedation. Use Caution/Monitor.hydroxyzinehydroxyzine and maprotiline both increase sedation. Use Caution/Monitor.hydroxyzine and maprotiline both increase QTc interval. Use Caution/Monitor.hyoscyaminehyoscyamine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayhyoscyamine spray and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.iloperidonemaprotiline and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.iloperidone and maprotiline both increase sedation. Use Caution/Monitor.imipramineimipramine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.imipramine and maprotiline both increase sedation. Use Caution/Monitor.indacaterol, inhaledindacaterol, inhaled, maprotiline. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.ipratropiumipratropium and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isoniazidmaprotiline and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.isoproterenolmaprotiline increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.ketamineketamine and maprotiline both increase sedation. Use Caution/Monitor.ketotifen, ophthalmicmaprotiline and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.L-tryptophanmaprotiline and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.lapatinibmaprotiline and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lasmiditanlasmiditan, maprotiline. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.lemborexantlemborexant, maprotiline. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.levalbuterolmaprotiline increases